The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data

dc.date.accessioned	2023-03-06T07:33:07Z
dc.date.available	2023-03-06T07:33:07Z
dc.date.issued	2023
dc.identifier.citation	Turk J Haematol. 2023 Feb 17. doi: 10.4274/tjh.galenos.2023.2022.0437. Online ahead of print.
dc.identifier.uri	https://hdl.handle.net/20.500.12619/100542
dc.relation.isversionof	10.4274/tjh.galenos.2023.2022.0437
dc.relation.isversionof	10.4274/tjh.galenos.2023.2022.0437
dc.title	The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data
dc.relation.journal	Turk J Haematol
dc.identifier.doi	10.4274/tjh.galenos.2023.2022.0437
dc.contributor.author	Aslaner Ak M
dc.contributor.author	Aslaner Ak M
dc.contributor.author	Gedük A
dc.contributor.author	Acar İH
dc.contributor.author	Polat MG
dc.contributor.author	Sunu C
dc.contributor.author	Bolaman AZ
dc.contributor.author	Hacıbekiroğlu T